​​​White
​
​Papers

Presentations
 ― European Society for Medical Oncology (ESMO): Poster presentation: Mortality after Rasburicase versus Allopurinol Anti-Hyperuricaemia Monotherapy in Patients with Liquid Tumours. authors: Cairo MS, Gallagher JR, Drea E, Barnes Y, Clark C, Carroll S (October 2023, Madrid, Spain)

​​― American Society of Hematology (ASH) 64th Annual Meeting, poster presentation: Fatalities from Tumor Lysis Syndrome (TLS) After Anti-Hyperuricemic Monotherapy – Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol; authors: Cairo MS, Gallagher JR, Barnes Y, Drea E, Carroll S. (December 2022, New Orleans, LA)
― Society of Hematologic Oncology (SOHO) 10th Annual Meeting: poster presentation: Comparison of Nationally Representative Samples of Rasburicase vs. Allopurinol Post-Hyperuricemia Monotherapy in Patients with Hematological Malignancies: Significant Reduction in Tumor Lysis Syndrome Mortality with Rasburicase; authors: Cairo MS, Gallagher JR, Barnes Y, Drea E, Carroll S. (September 2022, Houston, TX) Reprised Autumn 2022 at Florida Society of Clinical Oncology (FLASCO) SOHO Poster

―​ World Congress on Dermatology Research, J. Gallagher speaking (virtual), Tokyo, Japan, April 2022 

―​ 6th Annual Microbiome Movement Drug Development Europe Conference, J. Gallagher speaking, London (via webcast), January 25, 2022
―​ International Conference on Clinical & Experimental Dermatology & Cosmetic Surgery: Jack Ray Gallagher speaker: Rare genetic conditions in dermatology - Future practice implications: An underdiagnosed example. (October 2020 [rescheduled virtual], Vancouver, Canada)
― 4th Annual PCDI Global Obstetrics and Gynaecology Congress: Gallagher JR, presentation: Growing Importance of Real-World-Occurrence (RWO) Studies, a Recent Example – Adverse Events in PARP Inhibitor (Niraparib) Maintenance Treatment for Recurrent Ovarian Cancer (June 2019, Prague, Czech Republic)
― American Diabetes Association 79th Scientific Sessions: Mehta SN, Kruger DF, Bode BW, Layne JE, Dumais B, Gallagher JR, Ly TT: Effect of the Omnipod Insulin Management System on Glycemic Control in Adults with Type 1 Diabetes Previously Treated with MDI or CDIII (June 2019, San Francisco)
― European Society for Medical Oncology (ESMO): Gallagher JR, Heap KH, Carroll S: Poster presentation: Real world occurrence of top three clinical-trial reported adverse events of PARP inhibitor niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, a US-based retrospective observational study of a 200 mg/day starting-dose cohort (October 2018, Munich, Germany) 

—  American Academy of Neurology, poster on treatment for rare infantile spasms, 69th annual meeting (April 2017, Boston); also published as abstract in Neurology supplement (April 2017) Abstract; Poster

— International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 19th Annual European Congress,2 poster presentations on findings from an economic burden of illness study of a rare infection in Europe and Canada (November 2016, Vienna, Austria)  Poster1;  Poster2

— ISPOR, 18th Annual European Congress, retrospective observational study to capture economic burden evidence in a rare disease (November 2015, Milan, Italy) Abstract; Poster

— EphMRA (European Pharmaceutical Market Research Association), “Precedent and consequence research to undergird orphan reimbursement strategy – A multi-layered, non-traditional approach,” (June 2015, Amsterdam, Netherlands) Presentation

— Japanese Respiratory Society, Co-author, poster presentation on Clarity Pharma study comparing treatment patterns for a rare lung disease in EU5, Japan and US (April 2015, Tokyo, Japan) Abstract

— European Respiratory Society, Co-author of presentation on Clarity study of prevalence and incidence of a rare lung disease in Europe: Text and Poster1; co-author, comparisons of treatment patterns for the disease in EU5, Japan and US (September 2014, Munich, Germany) Text; Poster2

— KIT 2014 (Congress for Infectious Diseases and Tropical Medicine), co-author, rare lung infection prevalence in Germany (June 2014, Cologne) Abstract

— EphMRA Annual conference, fieldwork challenges debate, (June 2013, London) Presentation
— American Thoracic Society (ATS) International Conference, study of rare lung infection, co-written with 2 NIH epidemiologists (May 2013, Philadelphia) Abstract
— PMRG Institute (Pharmaceutical Marketing Research Group), cancer study and sample validity (October 2012, Philadelphia) Abstract; Poster
— PBIRG (Pharmaceutical Business Intelligence and Research Group), presentation on sample validity (May 2012, Chicago) Poster
— Market Research Society (MRS) Healthcare Research Conference, surveys (February 2012, London) Presentation
— Society of Urologic Oncology (SUO) Annual Meeting in conjunction with World Urologic Oncology Federation, cancer study (December 2011, Rockville, Md.) Poster
— American Urological Association (AUA) Annual Meeting, cancer study (May 2011, Washington, D.C. – one of 696 selected from 6,638 submissions) Abstract; Presentation
— ISPOR 16th Annual International Meeting, posters based on Clarity cancer study (May 2011, Baltimore, Md.) Presentation1; Presentation2
— ASCO, Duration of Therapy of Colony Stimulating Factors (May 2002) Paper

• Our research has withstood the scrutiny of peer-review journals and medical conferences, which can help you in showing evidence of value and efficacy to payors and regulators. 
   
  
• Clarity's co-investigators have contributed to medical research and have served at prestigious agencies, medical schools, and universities in the US and overseas.
  

© 2014-2023 Clarity Pharma Research® LLC  |  All Rights Reserved | Privacy Policy
To learn more about our services, contact information@claritypharma.com.

— Disadvantages of Commonly Used Alternatives to a Patient Records Approach (PDF)
— Sargramostim (GM-CSF) as Immunotherapy (PDF)
— CSF Efficacy and Other Key Attributes (PDF)
— National Representative Actinic Keratoses Study: Key Findings Among Dermatologists (PDF)
— National Representative Actinic Keratoses Study: Key Findings Among PCPs (PDF)
— National Descriptive Blood and Marrow Study: Transplants Performed in US (PDF)
— HIV / AIDS Anemia (PDF)
— Hepatitis C Treatment Associated Anemia (PDF)
— Metastatic Melanoma Treatment (PDF)
— Basal Cell Carcinoma Treatment (PDF)
— Metastatic Renal Cell Carcinoma Treatment (PDF)
— Undiagnosed Chronic Kidney Disease Among Rheumatoid Arthritis Patients (PDF)
— How Patient-Records Methodology Can Help Overcome Shortcomings of ATU and Syndicated Data (PDF)
— Why Peer-Reviewed Publications Matter to Your Business (PDF)

(April 2011) Citation
— Journal of Dermatological Treatment, article on actinic keratoses treatments and outcomes (2006) Abstract
— Journal of Health Care Marketing, article on a study of patient selection of orthopedists, podiatrists and PCPs for foot treatments, by Clarity chief scientist, reprinted in the book Health Care Marketing: A Foundation for Managed Quality (3rd ed., Philip D. Cooper, editor)  Abstract; Chapter
— Journal of Health Care Marketing, Violating assumptions of statistical procedures: JHCM reporting guidelines (September 1990) Abstract
— Journal of Health Care Marketing, Invalid Patient Surveys: Not a Bargain at Any Price (March 1989) Article
— Nursing Management, article on developing an optimal nurse staffing system (March 1987) Citation
— American Journal of Mental Deficiency, article on Dr. Gallagher's experimental study of short-term memory in the cognitively impaired. Citation
​— Changing Behavior: How and Why (book by Dr. Gallagher, Silver Burdett Professional Publications)

(Including nonproprietary findings for study physician participants and the public, with clients’ permission) 

Clarity and co-investigators have presented at a number of conferences.We presented this poster at the 2012 PMRG Institute (view PDF).

 CLARITY PHARMA RESEARCH ®
​PHARMACEUTICAL MARKET RESEARCH REPORTS BASED IN SCIENCE ™